The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Jun. 25, 1:43 PM

Slide #9. Paratek Pharmaceuticals, Inc. Secondary Offering

Company: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)
Date announced: 6/20/2016
Shares Offered: 4,250,000
Date of Pricing: 6/22/2016
Price Per Share: $13.00
Secondary Offering Details: Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. In addition, Paratek expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of its common stock sold in the offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Paratek. -updated 6/22- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the pricing of its underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $13.00 per share, before underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be sold by Paratek. In addition, Paratek has granted to the underwriters a 30-day option to purchase up to 637,500 additional shares of its common stock.

Paratek Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Co.'s first late-stage, lead antibacterial product candidate, omadacycline, is an antibiotic being developed for potential use as an empiric monotherapy for serious, community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Co.'s second late-stage, lead antibacterial product candidate, sarecycline, previously known as WC3035, is an once-daily, tetracycline-derived compound designed for use in the treatment of acne and rosacea.

PRTK SEC Filing Email Alerts Service

Open the PRTK Page at The Online Investor »

Company Name:  Paratek Pharmaceuticals Inc
Website:  www.transcept.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding PRTK:  15
Total Market Value Held by ETFs:  $4.15M
Total Market Capitalization:  $235.00M
% of Market Cap. Held by ETFs:  1.77%
 

Open the PRTK Page at The Online Investor (in a new window) »

June 25, 2016    1:43 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.